No Data
No Data
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a...
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Express News | Foghorn Therapeutics Inc.: Extends Cash Runway Into 2027